Fractional Exhaled Nitric Oxide as an Inflammatory Biomarker in Chronic Obstructive Pulmonary Disease (COPD) with or without Concurrent Diagnosis of Asthma: The Canadian Cohort Obstructive Lung Disease (CanCOLD)

References

• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013.
   PubMed Web of Science ®Google Scholar
• Kiljander T, Helin T, Venho K, et al. Prevalence of asthma-COPD overlap syndrome among primary care asthmatics with a smoking history: a cross-sectional study. NPJ Prim Care Respir Med. 2015;25:15047.
   PubMed Web of Science ®Google Scholar
• Burgel PR, Paillasseur JL, Roche N. Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities. Biomed Res Int. 2014;2014:420134. doi:10.1155/2014/420134.
   PubMed Web of Science ®Google Scholar
• Feng J-X, Lin Y, Lin J, et al. Relationship between fractional exhaled nitric oxide level and efficacy of inhaled corticosteroid in asthma-COPD overlap syndrome patients with different disease severity. J Korean Med Sci. 2017;32(3):439–447. doi:10.3346/jkms.2017.32.3.439.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873. doi:10.1183/09031936.00111707.
   PubMed Web of Science ®Google Scholar
• Smith LJ. The lower limit of normal versus a fixed ratio to assess airflow limitation: will the debate ever end? Eur Respir J. 2018;51(3):1800403. doi:10.1183/13993003.00403-2018.
   PubMed Web of Science ®Google Scholar
• Çolak Y, Afzal S, Nordestgaard BG, et al. Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study. Eur Respir J. 2018;51(3):1702681. doi:10.1183/13993003.02681-2017.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, National Center for Health Statistics. Third National Health and Nutrition Examination Survey, 1988–1994. NHANES III raw spirometry data file. Hyattsville MD: Centers for Disease Control and Prevention; 2001.
   Google Scholar
• Mikulski MA, Gerke AK, Lourens S, et al. Agreement between fixed-ratio and lower limit of normal spirometry interpretation protocols decreases with age: is there a need for a new GOLD standard? J Occup Environ Med. 2013;55(7):802–808. doi:10.1097/JOM.0b013e31828b22cc.
   PubMed Web of Science ®Google Scholar
• Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968. doi:10.1183/09031936.05.00035205.
   PubMed Web of Science ®Google Scholar
• Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179–187. doi:10.1164/ajrccm.159.1.9712108.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Asthma-COPD overlap. Chest. 2016;149(1):7–8. doi:10.1016/j.chest.2015.08.017.
   PubMed Web of Science ®Google Scholar
• From the Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2020.
   Google Scholar
• Hardin M Silverman EK, Barr RG, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12(1):127. doi:10.1186/1465-9921-12-127.
   PubMedGoogle Scholar
• Menezes AMB, Montes de Oca M, Perez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014;145(2):297–304. doi:10.1378/chest.13-0622.
   PubMed Web of Science ®Google Scholar
• Rhee CK, Yoon HK, Yoo KH, et al. Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma. COPD. 2014;11(2):163–170. doi:10.3109/15412555.2013.831061.
   PubMedGoogle Scholar
• Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med. 2015;373(13):1241–1249. doi:10.1056/NEJMra1411863.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–335. doi:10.1016/j.arbres.2017.03.018.
   PubMed Web of Science ®Google Scholar
• Koblizek V, Chlumsky J, Zindr V, et al. Chronic obstructive pulmonary disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(2):189–201. doi:10.5507/bp.2013.039.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bhutani M, Hernandez P, et al. CTS position statement: pharmacotherapy in patients with COPD—an update. Can J Respir Crit Care Sleep Med. 2017;1(4):222–241. doi:10.1080/24745332.2017.1395588.
   Web of Science ®Google Scholar
• Kankaanranta H, Harju T, Kilpelainen M, et al. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol. 2015;116(4):291–307. doi:10.1111/bcpt.12366.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Herje N, Crater G, et al. Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study. Int J Chron Obstruct Pulmon Dis. 2014;9:745–751.
   PubMed Web of Science ®Google Scholar
• Gao J, Zhang M, Zhou L, et al. Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD. COPD. 2017;12:1287–1293. doi:10.2147/COPD.S134998.
   Google Scholar
• Alving K, Malinovschi A. Basic aspects of exhaled nitric oxide. Eur Respir Monogr. 2010;49:1–31.
   Google Scholar
• Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615. doi:10.1164/rccm.9120-11ST.
   PubMed Web of Science ®Google Scholar
• Mostafavi-Pour-Manshadi SM, Naderi N, Barrecheguren M, et al. Investigating fractional exhaled nitric oxide in chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO): a scoping review. COPD. 2018;15(4):377–391. doi:10.1080/15412555.2018.1485637.
   PubMedGoogle Scholar
• Nanda CR, Singapuri A, Soares M, et al. Domiciliary exhaled nitric oxide and eosinophilic airway inflammation in adults with asthma. Eur Respir J. 2016;48(1):242–244. doi:10.1183/13993003.02060-2015.
   PubMed Web of Science ®Google Scholar
• Taylor DR, Pijnenburg MW, Smith AD, et al. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax. 2006;61(9):817–827. doi:10.1136/thx.2005.056093.
   PubMed Web of Science ®Google Scholar
• Price D, Ryan D, Burden A, et al. Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care. Clin Transl Allergy. 2013;3(1):37. doi:10.1186/2045-7022-3-37.
   PubMedGoogle Scholar
• Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. The Lancet. 2009;374(9691):733–743. doi:10.1016/S0140-6736(09)61303-9.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47(2):625–637. doi:10.1183/13993003.01170-2015.
   PubMed Web of Science ®Google Scholar
• Wurst KE, Rheault TR, Edwards L, et al. A comparison of COPD patients with and without ACOS in the ECLIPSE study. Eur Respir J. 2016;47(5):1559–1562. doi:10.1183/13993003.02045-2015.
   PubMed Web of Science ®Google Scholar
• Barrecheguren M, Roman-Rodriguez M, Miravitlles M. Is a previous diagnosis of asthma a reliable criterion for asthma-COPD overlap syndrome in a patient with COPD? Int J Chron Obstruct Pulmon Dis. 2015;10:1745–1752.
   PubMed Web of Science ®Google Scholar
• Barrecheguren M, Pinto L, Mostafavi-Pour-Manshadi S-M-Y, et al. Identification and definition of asthma-COPD overlap: The CanCOLD study. Respirology (Carlton, Vic). 2020. doi:10.1111/resp.13780.
   PubMed Web of Science ®Google Scholar
• Colak Y, Afzal S, Nordestgaard BG, et al. Combined value of exhaled nitric oxide and blood eosinophils in chronic airway disease: the Copenhagen General Population Study. Eur Respir J. 2018;52(2):1800616. doi:10.1183/13993003.00616-2018.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Tan WC, Benedetti A, et al. Canadian Cohort Obstructive Lung Disease (CanCOLD): fulfilling the need for longitudinal observational studies in COPD. COPD. 2014;11(2):125–132. doi:10.3109/15412555.2012.665520.
   PubMedGoogle Scholar
• Horvath I, Barnes PJ, Loukides S, et al. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. Eur Respir J. 2017;49(4).
   Web of Science ®Google Scholar
• American Thoracic Society/European Respiratory Society (ATS/ERS). ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med. 2005;171(8):912–930. doi:10.1164/rccm.200406-710ST
   PubMed Web of Science ®Google Scholar
• Olin AC, Rosengren A, Thelle DS, et al. Height, age, and atopy are associated with fraction of exhaled nitric oxide in a large adult general population sample. Chest. 2006;130(5):1319–1325. doi:10.1378/chest.130.5.1319.
   PubMed Web of Science ®Google Scholar
• Chen FJ, Huang XY, Liu YL, et al. Importance of fractional exhaled nitric oxide in the differentiation of asthma-COPD overlap syndrome, asthma, and COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2385–2390. doi:10.2147/COPD.S115378.
   PubMed Web of Science ®Google Scholar
• Alcazar-Navarrete B, Romero-Palacios PJ, Ruiz-Sancho A, et al. Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes. Nitric Oxide. 2016;54:67–72. doi:10.1016/j.niox.2016.02.003.
   PubMed Web of Science ®Google Scholar
• Tamada T, Sugiura H, Takahashi T, et al. Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations. Int J Chron Obstruct Pulmon Dis. 2015;10:2169–2176. doi:10.2147/COPD.S88274.
   PubMed Web of Science ®Google Scholar
• Montes de Oca M, Victorina Lopez Varela M, Laucho-Contreras ME, et al. Asthma-COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study. BMC Pulm Med. 2017;17(1):69–69. doi:10.1186/s12890-017-0414-6.
   PubMedGoogle Scholar
• Uchida A, Sakaue K, Inoue H. Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO). Allergol Int. 2018;67(2):165–171. doi:10.1016/j.alit.2018.02.002.
   PubMed Web of Science ®Google Scholar
• Wurst KE, St Laurent S, Hinds D, et al. Disease burden of patients with asthma/COPD overlap in a US claims database: impact of ICD-9 coding-based definitions. COPD. 2017;14(2):200–209. doi:10.1080/15412555.2016.1257598.
   PubMedGoogle Scholar
• Joo H, Han D, Lee JH, et al. Heterogeneity of asthma–COPD overlap syndrome. COPD. 2017;12:697–703. doi:10.2147/COPD.S130943.
   Google Scholar
• Kobayashi S, Hanagama M, Yamanda S, et al. Inflammatory biomarkers in asthma-COPD overlap syndrome. COPD. 2016;11:2117–2123. doi:10.2147/COPD.S113647.
   Google Scholar
• Rawy AM, Mansour AI. Fraction of exhaled nitric oxide measurement as a biomarker in asthma and COPD compared with local and systemic inflammatory markers. Egypt J Chest Dis Tuberc. 2015;64(1):13–20. doi:10.1016/j.ejcdt.2014.09.004.
   Web of Science ®Google Scholar
• Ji Z, Pan X, Ji F, et al. Fractional exhaled nitric oxide detection in treatment of asthma-chronic obstructive pulmonary disease overlap syndrome [Chinese]. Acad J Second Military Med Univ. 2016;37(10):1250–1255. ].
   Google Scholar
• Deng DD, Zhou AY, Shuang QC, et al. The value of fractionated exhaled nitric oxide in the diagnosis of asthma-chronic obstructive pulmonary disease overlap syndrome. Zhonghua Jie He He Hu Xi Za Zhi. 2017;40(2):98–101.
   PubMedGoogle Scholar
• Durmaz D, Goksu E, Kilic T, et al. The role of nitric oxide in predicting revisit of patients with exacerbated chronic obstructive pulmonary disease. J Emerg Med. 2015;48(2):247–253. doi:10.1016/j.jemermed.2014.06.026.
   PubMed Web of Science ®Google Scholar
• Xia Q, Pan P, Wang Z, et al. Fractional exhaled nitric oxide in bronchial inflammatory lung diseases. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014;39(4):365–370.
   PubMedGoogle Scholar
• Logotheti H, Pourzitaki C, Tsaousi G, et al. The role of exhaled nitric oxide in patients with chronic obstructive pulmonary disease undergoing laparotomy surgery - The noxious study. Nitric Oxide. 2016;61:62–68. doi:10.1016/j.niox.2016.10.005.
   PubMed Web of Science ®Google Scholar